NCT05143190View on ClinicalTrials.gov

Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

June 20, 2022

Study Completion Date

August 9, 2022

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
DRUG

PTR-01

Intravenous recombinant collagen 7

Trial Locations (2)

10032

Columbia University Irving Medical Center, New York

94063

Stanford University, Redwood City

Sponsors
All Listed Sponsors
collaborator

Phoenix Tissue Repair, a BridgeBio company

UNKNOWN

lead

Phoenix Tissue Repair, Inc.

INDUSTRY

NCT05143190 - Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01) | Biotech Hunter | Biotech Hunter